DEC 09, 2018 11:45 AM PST

Targeting CB1 Endocannabinoid Receptor: Specificity is the Key

WRITTEN BY: Amy Loriaux

The human endocannabinoid system (ECS) is one of the body's largest network of neurotransmitters, receptors, and neuromodulators. This system plays a role in a myriad of functions and disorders, from cancer, metabolic and eating disorders, neurodegeneration, locomotion, pain, liver disease, and immunosuppression. The CB1 receptor is the most abundant of the ECS receptors in the central nervous system (CNS) but is expressed at low concentrations in other organs, such as the spleen, lungs, etc. These receptors are primarily inhibitory, that is, they will attenuate nerve signaling, but their effects depend on where their receptors are located. For instance, there are CB1 receptors on the signaling (i.e. firing) neuron, which means endocannabinoids (ECs) can modulate neurons on both sides of the synapse.

Photo Source: UnSplash.com

The ubiquity of the CB1 receptor in the body and its role in many physiological mechanisms makes it a novel candidate for a therapeutic drug target. Scientists and pharmaceutical companies have been working to target this receptor for a while, but only a few have made it to market due to severe psychological side effects. For example, rimonabant, a CB1 antagonist used for the treatment of obesity, was in Phase III clinical trials before it was shelved due to the development of suicidal thoughts in patients.

So, this would seem that targeting the CB1 receptor is not a great idea. However, new evidence suggests that the CB1 receptor has multiple conformations or molecular arrangments and that they have what are called allosteric binding sites (see video below). Essentially, these are areas of the receptor other than the main binding site, which, if activated, can alter the way the receptor reacts to its specific ligand. Benzodiazepines and barbiturates work this way on the GABA-A receptor. Each of these allosteric sites may be exploited for therapeutic use. Allosteric binding pockets have amino acid sequences that may be more specific for each receptor.

Photo Source: UnSplash.com

Some drug companies are already using this specificity of allosteric binding on the CB1 receptor. The development of these drugs are right now in the nonclinical stage, that is essentially synthesizing compounds in the lab with the ability to target allosteric sites on the CB1 receptor. Many of these compounds are being tested using various in vitro assays to test proof of concept. Patents have been filed. If this technique is really as good as it is predicted to be, we may have a new medication on our hand to treat disorders from opioid addiction to cancer. We will have to wait and see. The video below has a visual aid for understanding allosteric modulators. Note: they refer to enzymes but the same can be said for receptors.

 

Video Source: Khan Academy

Sources: ACS Medical Chemistry Letters, Best Practice & Research: Clinical Endocrinology & Metabolism, Labroots.com, Wikipedia - Allosteric Modulation; Khan Acadamy

About the Author
  • I currently work at a small CRO involved in clinical trial management.
You May Also Like
SEP 20, 2019
Health & Medicine
SEP 20, 2019
Use of Highly Potent Marijuana Could Pose Risks for Adolecents
A 2018 biennial survey given to secondary school students in Arizona shows that one third of students in that age range have tried some form of marijuana,...
SEP 20, 2019
Cannabis Sciences
SEP 20, 2019
Will Cannabis Facilities Pollute the Air?
The strong smell of cannabis comes from chemicals that could potentially cause indoor or outdoor air pollution, if not properly managed, a new study finds....
SEP 29, 2019
Cannabis Sciences
SEP 29, 2019
CBD Alleviates Angelman Syndrome Seizures in Mice Trial
CBD has already been shown to be effective as an anti-anxiety, antipsychotic and anti-epileptic substance. Can it help youth and adults with a rare neurolo...
OCT 15, 2019
Drug Discovery & Development
OCT 15, 2019
Therapeutic To Treat The Detrimental Effects of Marijuana
As U.S. states continue to legalize the use of marijuana, so is the number of American women using cannabis before becoming pregnant and to treat morning s...
OCT 23, 2019
Cannabis Sciences
OCT 23, 2019
Why the Michael J. Fox Foundation Advocates for Cannabis Research
The Michael J. Fox Foundation for Parkinson’s Research (MJFF), which was established by and is named after the actor who has the disease, continues t...
NOV 05, 2019
Cannabis Sciences
NOV 05, 2019
Single Exposure to CBD & THC Disrupts Embryonic Development
It only takes one incidence of cannabinoid exposure during the first month of pregnancy to yield detrimental effects on a developing embryo. New research r...
Loading Comments...